Stockscreener 앱 받기
1.73
7.98%
-0.15
시간 외 거래:
1.75
0.02
+1.16%
전일 마감가:
$1.88
열려 있는:
$1.87
하루 거래량:
887.22K
Relative Volume:
2.57
시가총액:
$86.78M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-21.72%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.68
$1.87
1주일 범위
$1.42
$2.26
52주 변동 폭
$1.42
$2.30
Mindwalk Holdings Corp Stock (HYFT) Company Profile
HYFT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HYFT
Mindwalk Holdings Corp
|
1.73 | 86.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Mindwalk Holdings Corp Stock (HYFT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-10-25 | 개시 | The Benchmark Company | Buy |
Mindwalk Holdings Corp 주식(HYFT)의 최신 뉴스
MindWalk : Accelerating Drug Discovery through First End-to-End Bio-Native AI Platform - MarketScreener
How MindWalk Holdings' Rebranding and Improved Earnings May Impact HYFT Investors - Yahoo Finance
MindWalk Holdings Reports Strong Revenue Growth and Improved Margins - TipRanks
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Rebranding - GuruFocus
MindWalk Holdings Reports Q3 2025 Financial Results and Strategic Growth - TipRanks
MindWalk Holdings Corp reports results for the quarter ended July 31Earnings Summary - TradingView
MindWalk Holdings Reports Record Revenue and Strategic Divestiture - TipRanks
MindWalk Holdings Corp. Reports Earnings Results for the First Quarter Ended July 31, 2025 - MarketScreener
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly - PharmiWeb.com
Earnings call transcript: MindWalk Inc. reports strong Q1 2025 performance, rebrands from ImmunoPrecise Antibodies - Investing.com UK
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet - Business Wire
MindWalk : 2025 Combined Financial Statements - MarketScreener
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 - Business Wire
MindWalk Holdings Corp. (HYFT) - Zacks Investment Research
HYFT Stock Price and Chart — NASDAQ:HYFT - TradingView
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT By Investing.com - Investing.com Canada
HYFT's Rebranding: A Strategic Pivot in Biotech's AI-Driven Future - AInvest
ImmunoPrecise Antibodies rebrands as MindWalk, changes ticker to HYFT - Investing.com
Immunoprecise rebrands as Mindwalk, announces Nasdaq ticker change to "HYFT" - MarketScreener
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” - FinancialContent
ImmunoPrecise Antibodies Ltd. has Changed its Name to MindWalk - MarketScreener
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation - Business Wire
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA - Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 - MarketScreener
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors - MarketScreener
Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data - Business Wire
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies - Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery - Business Wire
IPA's LENSai Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - MarketScreener
ImmunoPrecise Antibodies Ltd.'s Lensai?? Platform Delivers X-Ray-Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - MarketScreener
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - MarketScreener
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - Business Wire
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 - MarketScreener
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 - MarketScreener
ImmunoPrecise Antibodies Announces Key Leadership Changes - MarketScreener
Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO - MarketScreener
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - MarketScreener
IPA Announces Resignation of Chief Financial Officer - MarketScreener
MindWalk Holdings Corp. (HYFT) Q2 FY2025 earnings call transcript - Yahoo Finance
ImmunoPrecise to Host TECHDAY: Cutting Edge AI and Biologics Innovation Form 6 K - MarketScreener
Immunoprecise Antibodies Successfully Engineers in Silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology - MarketScreener
Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand - MarketScreener
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform - MarketScreener
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology - MarketScreener
Mindwalk Holdings Corp (HYFT) 재무 분석
Mindwalk Holdings Corp (HYFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):